Technology company Hydrix has partnered with medical device developer Angel Medical Systems (AngelMed) for exclusive rights to distribute a heart attack alerting device in Australia.
Furthermore, the deal allows Hydrix to provide the AngelMed Guardian System in multiple other Asian markets, including Japan and Singapore.
Guardian is a cardiac monitoring device to notify patients in case of an imminent acute coronary syndrome (ACS) episode such as heart attacks and unstable angina, designed for patients with a history of ACS and who are at high risk for recurrent episodes.
The device offers continuous monitoring of a patient’s heart signal and leverages artificial intelligence (AI) to identify an impending heart attack.
Upon identification of suspicious heart activity, the AngelMed Guardian System instantly alerts the patient via vibration within the chest. Also, a separate wireless device notifies patients with sound and flashing LEDs.
The implant detects ACS symptoms accurately than the patient alone. Guardian is meant to minimise the uncertainty associated with self-diagnosis, added the company.
Around 900 patients were implanted with the device in clinical trials performed in the US.
Data showed lower morbidity rates, better patient quality of life, decrease in heart damage and length of hospital stay, resulting in reduced healthcare costs for patients.
Hydrix CEO Peter Lewis said: “The Guardian is part of Hydrix’s commitment to developing products and technologies which help improve the quality of life for patients around the world.
“We look forward to a long relationship with AngelMed as we help make the Guardian System become the new standard of cardiac patient care in the Asia Pacific.”
The Guardian System is scheduled to launch in Australia in 2021, subject to regulatory approval.